EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two‐Injection Start Regimen with Aripiprazole Once‐Monthly Long‐Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder

Yumiko Yamasaki iD, Tomohiro Sasaki, Antal Martinecz, Mayumi Hasegawa, Kazuo Kuwahara, Ayaka Soga, Kai Yamada, Satoshi Katayama, Kenji Maeda, Takako Ichimura, Yosuke Kawai

The Journal of Clinical Pharmacology · 2026-07 · 66 (7)

DOI: 10.1002/jcph.70230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 07.07.2026. Verfasst von Yumiko Yamasaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Department of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Minato-ku, Tokyo, J…. Hauptthemen laut MEDLINE: Aripiprazole, Schizophrenia, Antipsychotic Agents, Models, Biological. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc, Otsuka Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To improve medication adherence in Japanese patients with schizophrenia or bipolar I disorder, this population pharmacokinetic (popPK) modeling and simulation was conducted to support the regulatory submission of the two‐injection start (TIS; two aripiprazole once‐monthly long‐acting injectable [LAI; 400 mg each] administered at different sites, along with a single oral dose of aripiprazole [6–15 mg]) regimen by comparing it with the original regimen (single LAI with 2‐week concomitant oral dose of aripiprazole [6–15 mg]). Pharmacokinetic data from four Japanese clinical trials in patients with schizophrenia were used to externally validate and update a previously validated popPK model developed from seven non‐Japanese trials in healthy subjects or in patients with schizophrenia/schizoaffective disorders. Simulations were conducted assuming two types of patients: with and without prior stabilization on oral aripiprazole. The dataset of 1123 participants (13,985 observations) from clinical trials, including 306 Japanese patients (5699 observations) from Japanese clinical trials, was used as the input in the popPK model. Simulations showed that the plasma concentration–time profiles of the original regimen and the TIS regimen were similar in the Japanese population. In addition, the currently available postmarketing safety data did not show any new safety concerns and/or an incremental safety risk with the TIS regimen compared with the original regimen. The aripiprazole TIS regimen provides a new option by reducing the oral aripiprazole administration period to a single day. This is expected to reduce the medication burden on patients and, consequently, reduce the burden on healthcare professionals and caregivers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleSchizophreniaAntipsychotic AgentsModels, BiologicalBipolar DisorderHumansInjections, IntramuscularAdultMaleFemaleJapanDelayed-Action PreparationsMiddle AgedComputer SimulationYoung AdultDrug Administration ScheduleEast Asian People

Stichwörter der Autor:innen

Japanaripiprazolebipolar I disorderpopulation pharmacokinetic modelingschizophreniatwo‐injection start regimen

Substanzen

AripiprazoleAntipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Office of Clinical Pharmacology, Department of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Minato-ku, Tokyo, Japan.
  • Office of Clinical Pharmacology, Department of Biometrics, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan.
  • Certara Drug Development Solutions, Certara USA Inc., Radnor, PA, USA.
  • Clinical Development, Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Minato-ku, Tokyo, Japan.
  • Department of Medical Safety, Otsuka Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan.
  • Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan.

ORCID-Profile: Yumiko Yamasaki

Förderung

  • Otsuka Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Development & Commercialization, Inc
  • Otsuka Pharmaceutical

Zitieren

APA

Yamasaki, Y., Sasaki, T., Martinecz, A., Hasegawa, M., Kuwahara, K., Soga, A., Yamada, K., Katayama, S., Maeda, K., Ichimura, T., & Kawai, Y. (2026). Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two‐Injection Start Regimen with Aripiprazole Once‐Monthly Long‐Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder. The Journal of Clinical Pharmacology, 66(7). https://doi.org/10.1002/jcph.70230

Vancouver

Yamasaki Y, Sasaki T, Martinecz A, Hasegawa M, Kuwahara K, Soga A, et al. Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two‐Injection Start Regimen with Aripiprazole Once‐Monthly Long‐Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder. The Journal of Clinical Pharmacology. 2026;66(7). doi:10.1002/jcph.70230

BibTeX
@article{Yamasaki2026,
  author = {Yamasaki, Yumiko and Sasaki, Tomohiro and Martinecz, Antal and Hasegawa, Mayumi and Kuwahara, Kazuo and Soga, Ayaka and Yamada, Kai and Katayama, Satoshi and Maeda, Kenji and Ichimura, Takako and Kawai, Yosuke},
  title = {Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two‐Injection Start Regimen with Aripiprazole Once‐Monthly Long‐Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {7},
  doi = {10.1002/jcph.70230}
}
Kostenlos starten →